{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T20:21:06Z","timestamp":1770236466347,"version":"3.49.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T00:00:00Z","timestamp":1763683200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T00:00:00Z","timestamp":1763683200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Almirall S.A."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s13555-025-01603-y","type":"journal-article","created":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T16:00:18Z","timestamp":1763740818000},"page":"487-497","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Indirect Comparison of Cal\/BDP PAD-Cream vs Cal\/BDP Foam in Patients with Plaque Psoriasis Meeting the Rule of Tens"],"prefix":"10.1007","volume":"16","author":[{"given":"Anna","family":"Campanati","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar","family":"Llamas-Velasco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johannes","family":"Wohlrab","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rituparna","family":"Banerjee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Carles","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jordi","family":"Galv\u00e1n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seila","family":"Lorenzo-Herrero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jes\u00fas","family":"Cuervo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos","family":"Crespo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,21]]},"reference":[{"key":"1603_CR1","doi-asserted-by":"publisher","DOI":"10.2340\/ACTADV.V105.42945","volume":"105","author":"C Skayem","year":"2025","unstructured":"Skayem C, Taieb C, Halioua B, Baissac C, Saint Aroman M. Epidemiology of psoriasis: a worldwide global study. Acta Derm Venereol. 2025;105:42945. https:\/\/doi.org\/10.2340\/ACTADV.V105.42945.","journal-title":"Acta Derm Venereol"},{"issue":"6","key":"1603_CR2","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/j.mpmed.2017.03.010","volume":"45","author":"E Higgins","year":"2017","unstructured":"Higgins E. Psoriasis. Medicine. 2017;45(6):368\u201378. https:\/\/doi.org\/10.1016\/j.mpmed.2017.03.010.","journal-title":"Medicine"},{"issue":"2","key":"1603_CR3","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/J.JAAD.2020.07.087","volume":"84","author":"CA Elmets","year":"2021","unstructured":"Elmets CA, Korman NJ, Prater EF, Wong EB, Rupani RN, Kivelevitch D, et al. Joint AAD\u2013NPF guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures. J Am Acad Dermatol. 2021;84(2):432\u201370. https:\/\/doi.org\/10.1016\/J.JAAD.2020.07.087.","journal-title":"J Am Acad Dermatol"},{"key":"1603_CR4","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/1477-7525-4-35","volume":"4","author":"MJ Bhosle","year":"2006","unstructured":"Bhosle MJ, Kulkarni A, Feldman SR, et al. Quality of life in patients with psoriasis. Health Qual Life Outcomes. 2006;4:35. https:\/\/doi.org\/10.1186\/1477-7525-4-35.","journal-title":"Health Qual Life Outcomes"},{"issue":"6","key":"1603_CR5","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1016\/J.ADENGL.2012.12.003","volume":"104","author":"L Puig","year":"2013","unstructured":"Puig L, Carrascosa JM, Belinch\u00f3n I, Fern\u00e1ndez-Redondo V, Carretero G, Ruiz-Carrascosa JC, et al. Adherence and patient satisfaction with topical treatment in psoriasis, and the use, and organoleptic properties of such treatments: a Delphi study with an expert panel and members of the Psoriasis Group of the Spanish Academy of Dermatology and Venereology. Actas Dermosifiliogr. 2013;104(6):488\u201396. https:\/\/doi.org\/10.1016\/J.ADENGL.2012.12.003.","journal-title":"Actas Dermosifiliogr"},{"key":"1603_CR6","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1111\/J.1365-2133.2005.06502.X","volume":"152","author":"AY Finlay","year":"2005","unstructured":"Finlay AY. Current severe psoriasis and the rule of tens. Br J Dermatol. 2005;152:861\u20137. https:\/\/doi.org\/10.1111\/J.1365-2133.2005.06502.X.","journal-title":"Br J Dermatol"},{"key":"1603_CR7","doi-asserted-by":"publisher","first-page":"2153","DOI":"10.1007\/S13555-023-01003-0","volume":"13","author":"T Torres","year":"2023","unstructured":"Torres T, Galv\u00e1n J, Crutchley N, et al. Calcipotriol and betamethasone dipropionate cream based on PAD technology for the treatment of plaque psoriasis: a narrative review. Dermatol Ther (Heidelb). 2023;13:2153. https:\/\/doi.org\/10.1007\/S13555-023-01003-0.","journal-title":"Dermatol Ther (Heidelb)"},{"key":"1603_CR8","doi-asserted-by":"publisher","first-page":"97","DOI":"10.2147\/PTT.S63127","volume":"5","author":"C Rogalski","year":"2015","unstructured":"Rogalski C. Calcipotriol\/betamethasone for the treatment of psoriasis: efficacy, safety, and patient acceptability. Psoriasis (Auckl). 2015;5:97. https:\/\/doi.org\/10.2147\/PTT.S63127.","journal-title":"Psoriasis (Auckl)"},{"key":"1603_CR9","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1111\/J.1468-3083.2011.04060.X","volume":"25","author":"A Bewley","year":"2011","unstructured":"Bewley A, Page B. Maximizing patient adherence for optimal outcomes in psoriasis. J Eur Acad Dermatol Venereol. 2011;25:9\u201314. https:\/\/doi.org\/10.1111\/J.1468-3083.2011.04060.X.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1603_CR10","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005028.PUB3","volume":"2013","author":"AR Mason","year":"2013","unstructured":"Mason AR, Mason J, Cork M, et al. Topical treatments for chronic plaque psoriasis. Cochrane Database Syst Rev. 2013;2013:CD005028. https:\/\/doi.org\/10.1002\/14651858.CD005028.PUB3.","journal-title":"Cochrane Database Syst Rev"},{"key":"1603_CR11","doi-asserted-by":"publisher","first-page":"242","DOI":"10.36849\/JDD.6611","volume":"21","author":"AW Armstrong","year":"2022","unstructured":"Armstrong AW, Pinter A, Selmer J, et al. Pooled analysis demonstrating superior patient-reported psoriasis treatment outcomes for calcipotriene\/betamethasone dipropionate cream versus suspension\/gel. J Drugs Dermatol. 2022;21:242\u20138. https:\/\/doi.org\/10.36849\/JDD.6611.","journal-title":"J Drugs Dermatol"},{"key":"1603_CR12","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1111\/JDV.17734","volume":"36","author":"A Pinter","year":"2022","unstructured":"Pinter A, Green LJ, Selmer J, et al. A pooled analysis of randomized, controlled, phase 3 trials investigating the efficacy and safety of a novel, fixed dose calcipotriene and betamethasone dipropionate cream for the topical treatment of plaque psoriasis. J Eur Acad Dermatol Venereol. 2022;36:228\u201336. https:\/\/doi.org\/10.1111\/JDV.17734.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1603_CR13","doi-asserted-by":"publisher","first-page":"420","DOI":"10.36849\/JDD.5653","volume":"20","author":"LS Gold","year":"2021","unstructured":"Gold LS, Green LJ, Dhawan S, et al. A phase 3, randomized trial demonstrating the improved efficacy and patient acceptability of fixed dose calcipotriene and betamethasone dipropionate cream. J Drugs Dermatol. 2021;20:420\u20135. https:\/\/doi.org\/10.36849\/JDD.5653.","journal-title":"J Drugs Dermatol"},{"key":"1603_CR14","doi-asserted-by":"publisher","first-page":"2327","DOI":"10.1111\/JDV.19330","volume":"37","author":"A Pinter","year":"2023","unstructured":"Pinter A, Reich A, Arenberger P, et al. Randomized phase 3 trial demonstrating high efficacy, favourable safety and convenience of a novel calcipotriol and betamethasone dipropionate cream for the treatment of psoriasis. J Eur Acad Dermatol Venereol. 2023;37:2327\u201335. https:\/\/doi.org\/10.1111\/JDV.19330.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1603_CR15","doi-asserted-by":"publisher","first-page":"3191","DOI":"10.1080\/09546634.2022.2116924","volume":"33","author":"A Bewley","year":"2022","unstructured":"Bewley A, Barker E, Baker H, et al. An anchored matching-adjusted indirect comparison of fixed-dose combination calcipotriol and betamethasone dipropionate (Cal\/BDP) cream versus Cal\/BDP foam for the treatment of psoriasis. J Dermatol Treat. 2022;33:3191\u20138. https:\/\/doi.org\/10.1080\/09546634.2022.2116924.","journal-title":"J Dermatol Treat"},{"key":"1603_CR16","doi-asserted-by":"publisher","first-page":"3005","DOI":"10.1080\/09546634.2022.2095330","volume":"33","author":"KA Papp","year":"2022","unstructured":"Papp KA, Thoning H, Gerdes S, et al. Matching-adjusted indirect comparison of efficacy outcomes in trials of calcipotriol plus betamethasone dipropionate foam and cream formulations for the treatment of plaque psoriasis. J Dermatol Treat. 2022;33:3005\u201313. https:\/\/doi.org\/10.1080\/09546634.2022.2095330.","journal-title":"J Dermatol Treat"},{"key":"1603_CR17","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1007\/S13555-023-00979-Z","volume":"13","author":"L Stein Gold","year":"2023","unstructured":"Stein Gold L, Pinter A, Armstrong A, et al. Calcipotriene and betamethasone dipropionate PAD-cream demonstrates greater treatment efficacy in patients with moderate-to-severe psoriasis compared to topical suspension\/gel: a subgroup analysis of two phase 3 studies. Dermatol Ther (Heidelb). 2023;13:2031\u201344. https:\/\/doi.org\/10.1007\/S13555-023-00979-Z.","journal-title":"Dermatol Ther (Heidelb)"},{"key":"1603_CR18","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1007\/S40257-017-0258-0","volume":"18","author":"C Paul","year":"2017","unstructured":"Paul C, Leonardi C, Menter A, et al. Calcipotriol plus betamethasone dipropionate aerosol foam in patients with moderate-to-severe psoriasis: sub-group analysis of the PSO-ABLE study. Am J Clin Dermatol. 2017;18:405\u201311. https:\/\/doi.org\/10.1007\/S40257-017-0258-0.","journal-title":"Am J Clin Dermatol"},{"key":"1603_CR19","doi-asserted-by":"publisher","first-page":"58","DOI":"10.3390\/JMAHP12020006\/S1","volume":"12","author":"B Macabeo","year":"2024","unstructured":"Macabeo B, Quen\u00e9chdu A, Aball\u00e9a S, et al. Methods for indirect treatment comparison: results from a systematic literature review. J Mark Access Health Policy. 2024;12:58\u201380. https:\/\/doi.org\/10.3390\/JMAHP12020006\/S1.","journal-title":"J Mark Access Health Policy"},{"issue":"2","key":"1603_CR20","doi-asserted-by":"publisher","DOI":"10.1177\/0272989X17725740","volume":"38","author":"DM Phillippo","year":"2017","unstructured":"Phillippo DM, Ades AE, Dias S, Palmer S, Abrams KR, Welton NJ. Methods for population-adjusted indirect comparisons in health technology appraisal. Med Decis Mak. 2017;38(2):200. https:\/\/doi.org\/10.1177\/0272989X17725740.","journal-title":"Med Decis Mak"},{"issue":"8","key":"1603_CR21","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1111\/JDV.14277","volume":"31","author":"L Iversen","year":"2017","unstructured":"Iversen L, Dauden E, Segaert S, Freeman K, Magina S, Rigopoulos D, et al. Reformulations of well-known active ingredients in the topical treatment of psoriasis vulgaris can improve clinical outcomes for patients. J Eur Acad Dermatol Venereol. 2017;31(8):1271\u201384. https:\/\/doi.org\/10.1111\/JDV.14277.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"7","key":"1603_CR22","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1080\/09546634.2018.1544410","volume":"30","author":"V Vasconcelos","year":"2019","unstructured":"Vasconcelos V, Teixeira A, Almeida V, Teixeira M, Ramos S, Torres T, et al. Patient preferences for attributes of topical anti-psoriatic medicines. J Dermatol Treat. 2019;30(7):659\u201363. https:\/\/doi.org\/10.1080\/09546634.2018.1544410.","journal-title":"J Dermatol Treat"},{"key":"1603_CR23","doi-asserted-by":"publisher","first-page":"617","DOI":"10.3390\/PH16040617","volume":"16","author":"R Oliveira","year":"2023","unstructured":"Oliveira R, Almeida IF. Patient-centric design of topical dermatological medicines. Pharmaceuticals. 2023;16:617. https:\/\/doi.org\/10.3390\/PH16040617.","journal-title":"Pharmaceuticals"},{"key":"1603_CR24","doi-asserted-by":"publisher","first-page":"326","DOI":"10.36849\/JDD.7372","volume":"22","author":"A Curcio","year":"2023","unstructured":"Curcio A, Kontzias C, Gorodokin B, et al. Patient preferences in topical psoriasis treatment. J Drugs Dermatol. 2023;22:326\u20139. https:\/\/doi.org\/10.36849\/JDD.7372.","journal-title":"J Drugs Dermatol"},{"key":"1603_CR25","doi-asserted-by":"publisher","first-page":"607","DOI":"10.36849\/JDD.7993","volume":"23","author":"LH Kircik","year":"2024","unstructured":"Kircik LH, Draelos ZD, Glick B, et al. Preference for Cal\/BDP cream or foam in patients with mild to moderate plaque psoriasis. J Drugs Dermatol. 2024;23:607\u201311. https:\/\/doi.org\/10.36849\/JDD.7993.","journal-title":"J Drugs Dermatol"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01603-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-025-01603-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01603-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T07:40:27Z","timestamp":1770190827000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-025-01603-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,21]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["1603"],"URL":"https:\/\/doi.org\/10.1007\/s13555-025-01603-y","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,21]]},"assertion":[{"value":"30 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Anna Campanati received funding from Almirall S.A. and is an Editorial Board member of Dermatology and Therapy. Anna Campanati was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Mar Llamas-Velasco and Johannes Wohlrab received funding from Almirall S.A. Rituparna Banerjee, Anna Carles and Jordi Galv\u00e1n are employees at Almirall S.A. Seila Lorenzo-Herrero, Jes\u00fas Cuervo and Carlos Crespo are consultants of Axentiva Solutions S.L., which received consultancy fees from Almirall S.A. and, during the conduct of this study, from other pharmaceutical companies in unrelated projects.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}